You are here: Industry Insights > Roche

News List

Gilead, looking for cancer sales, swipes Roche pharma chief Daniel O'Day for CEO post fiercepharma
December 11, 2018
With Gilead’s CEO on the way out and revenues tumbling, the company needs a leader who can pump up cancer sales. And it may have found just that in the ranks of the world's biggest cancer drug maker.
Roche’s Daniel O’Day to become Gilead's chief executive pharmatimes
December 11, 2018
Gilead Sciences has announced that Daniel O'Day, the current chief executive (CEO) of Roche's pharmaceutical unit, will become its chief executive effective from March 1 next year.
FDA priority tag sets Roche's Tecentriq up for $1.5B expansion fiercepharma
December 10, 2018
Roche’s Tecentriq is closing in on a billion-dollar-plus lung cancer market that it can have all to itself.
Roche’s Tecentriq wins key lung cancer approval. Its prize? A showdown with formidable Merck fiercepharma
December 10, 2018
Merck’s Keytruda finally has some immuno-oncology competition in the previously untreated non-small cell lung cancer market, courtesy of Roche and its freshly minted Tecentriq-Avastin combo.
Roche’s Tecentriq gets FDA priority review to treat small cell lung cancer pharmaceutical-technology
December 10, 2018
The US Food and Drug Administration (FDA) has granted priority review for Roche’s Tecentriq (atezolizumab) in combination with chemotherapy for treating extensive-stage small cell lung cancer (ES – SCLC).....
FDA grants priority review to Roche's Tecentriq in combination with chemotherapy for the initial treatment of extensive-stage small cell lung cancer worldpharmanews
December 10, 2018
Roche announced that the US Food and Drug Administration (FDA) has accepted the company's supplemental Biologics License Application (sBLA) and granted Priority Review for Tecentriq®
Roche’s Kadcyla cuts risk of breast cancer recurrence after surgery pharmatimes
December 07, 2018
Roche’s Kadcyla was significantly better than Herceptin at reducing the risk of breast cancer recurrence in certain patients with residual disease after surgery, according to new study findings presented at the San Antonio Breast Cancer Symposium.
Roche unveils data for Kadcyla move into early breast cancer fiercepharma
December 06, 2018
Roche is hoping to grow sales for new drugs as biosim competition begins to erode its top blockbusters, and now the drugmaker has unveiled new data that just might give its breast cancer drug Kadcyla a boost.
Roche's Hemlibra shows sustained bleed control in children pharmatimes
December 06, 2018
Roche's Hemlibra has shown sustained bleed control in a late-stage trial involving 85 children with haemophilia A.
Roche aims for Kadcyla expansion with new early breast cancer data fiercepharma
December 06, 2018
Roche is hoping to grow sales for new drugs as biosim competition begins to erode its top blockbusters, and now the drugmaker has unveiled new data that just might give its breast cancer drug Kadcyla a boost.

Previous page 1 2 3 4 5 6 7 8 9 10 ... 45 46 Next page